Skip to main content
Cardiolucent

Condition

Cardiometabolic disease

Conditions

Cardiometabolic disease is the convergence of metabolic disorders — insulin resistance, obesity (particularly visceral adiposity), dyslipidemia, and hypertension — with cardiovascular disease. Rather than treating each component as a separate problem, cardiometabolic care recognizes that these conditions share root causes and amplify one another, so addressing them as an integrated system is dramatically more effective than chasing one number at a time. The arrival of GLP-1 receptor agonists and SGLT2 inhibitors has transformed what is possible in this space, both for weight and glucose and for cardiovascular and kidney outcomes. Dr. Kedan structures cardiometabolic care around the upstream drivers — visceral fat, insulin signaling, inflammation, sleep, and activity — and tracks the entire panel rather than letting one optimized lab value mask drift in another.

What Cardiolucent Evaluates

  • Comprehensive metabolic panel, HbA1c, fasting glucose and insulin, and HOMA-IR
  • Advanced lipid panel including ApoB, Lp(a), and triglyceride patterns
  • Body composition review including waist circumference and visceral adiposity
  • Liver enzymes and screening for metabolic dysfunction-associated steatotic liver disease (MASLD)
  • Blood pressure trends from home and ambulatory monitoring
  • Sleep history and screening for obstructive sleep apnea
  • Echocardiography with POCUS for structural and functional assessment
  • GLP-1 receptor agonist and SGLT2 inhibitor candidacy review

Common Symptoms

  • Many patients feel well early on — the disease is identified through lab and imaging patterns
  • Gradual weight gain, particularly central or abdominal
  • Fatigue, brain fog, or post-meal sluggishness
  • Increased thirst, urination, or unexplained hunger in established insulin resistance
  • Reduced exercise tolerance or shortness of breath as cardiac strain develops
  • Skin changes such as acanthosis nigricans (dark velvety patches in skin folds)
  • Symptoms of associated conditions: sleep apnea, MASLD, hypertension, PCOS

Risk Factors

  • Family history of diabetes, obesity, or early heart disease
  • Sedentary lifestyle and poor sleep quality
  • Diet patterns high in refined carbohydrates, ultra-processed foods, and sugar-sweetened beverages
  • Visceral obesity, even at normal BMI in some ethnic groups
  • Polycystic ovary syndrome (PCOS) and gestational diabetes history
  • Hispanic, South Asian, East Asian, and African American ancestry, which carry higher metabolic risk
  • Chronic stress and circadian disruption
  • Certain medications including some antipsychotics and steroids

How Cardiolucent Approaches Treatment

Dr. Kedan treats cardiometabolic disease as a single connected process rather than a list of isolated diagnoses. Lifestyle work is foundational — structured nutrition, resistance and aerobic training, sleep optimization, stress management — and is paired with carefully chosen medications when biology demands more. GLP-1 receptor agonists are considered for patients who will benefit from their combined weight, glucose, and cardiovascular effects, and SGLT2 inhibitors are used for their independent cardiovascular and kidney protection. The concierge model is well suited to this kind of care: visits are long enough to actually plan and revise meaningfully, and between-visit access lets Dr. Kedan fine-tune dosing, monitor side effects, and track the whole metabolic panel over time.

Common Questions

Frequently Asked Questions

What is cardiometabolic disease?
Cardiometabolic disease is the convergence of metabolic disorders — insulin resistance, obesity, dyslipidemia, and high blood pressure — with cardiovascular disease. Rather than treating each piece in isolation, this framework recognizes that they share root causes and amplify one another. Addressing them as a connected system is far more effective than chasing one number at a time.
How is it different from just having multiple conditions?
A patient with hypertension, prediabetes, and high cholesterol does not have three separate problems; they have one underlying metabolic process expressing itself in multiple ways. Treating cardiometabolic disease means modifying the upstream drivers — visceral fat, insulin resistance, inflammation, and lifestyle patterns — not just the downstream lab values. Dr. Kedan structures care around that integrated picture.
What does the evaluation involve?
Assessment typically includes a comprehensive metabolic and lipid panel, advanced lipid testing, glucose and insulin metrics, body composition review, blood pressure trends, and cardiovascular risk imaging when appropriate. POCUS during the visit adds direct information about cardiac structure and function. The result is a complete metabolic and cardiac portrait, not a list of isolated numbers.
Can cardiometabolic disease be reversed?
Many components — insulin resistance, fatty liver, prediabetes, hypertension, dyslipidemia — can improve substantially or normalize with the right combination of weight optimization, nutrition, exercise, sleep, and targeted medication. The earlier the intervention, the more reversible the picture tends to be. Even in advanced cases, the trajectory can be meaningfully changed.
Where do GLP-1 medications and SGLT2 inhibitors fit in?
These newer medications have transformed cardiometabolic care. GLP-1 receptor agonists improve weight, glucose, and cardiovascular outcomes, while SGLT2 inhibitors lower cardiovascular and kidney risk independently of glucose effects. Dr. Kedan considers them when they are likely to add meaningful benefit and reviews dosing, side effects, and cost so the decision is fully informed.
How much of this can be addressed with lifestyle alone?
Lifestyle is foundational and, for many patients in earlier stages, can do most of the work. A structured combination of nutrition change, resistance and aerobic training, sleep optimization, and stress management often improves several metabolic markers simultaneously. Medication is added when lifestyle alone cannot reach safe targets or when cardiovascular risk demands faster control.
How is progress measured?
Dr. Kedan tracks a range of indicators over time — blood pressure trends, lipid panels, HbA1c and fasting glucose, weight and body composition, and cardiac structure on echocardiography when appropriate. Progress is judged across the panel rather than by a single number, which avoids the false reassurance of one good lab value while others drift.
Is cardiometabolic disease hereditary?
Genetics contribute significantly to insulin resistance, body fat distribution, and lipid patterns, and a strong family history of diabetes, early heart disease, or obesity raises your baseline risk. Genetics are not destiny, however, and patients with strong family histories often respond particularly well to early, structured intervention. Schedule a consultation with Dr. Kedan to map your individual risk and design a prevention plan.
How often will I be seen?
Active phases of treatment — starting new medications, working toward weight or glucose goals — typically involve visits every 2–3 months. Once stable, visits move to every 4–6 months with home monitoring in between. The concierge model allows for direct communication between visits so adjustments can be made quickly when needed.

Explore

Related Conditions

Ready to learn more about Cardiometabolic disease?

Schedule a private consultation with Dr. Kedan in Beverly Hills.
Schedule an Appointment

Medical Disclaimer

The information on this site is for general educational purposes only and is not medical advice, diagnosis, or treatment. Reading this site does not create a doctor–patient relationship. Always consult a qualified healthcare professional for personal guidance. If this is an emergency, call 911. Mentions of medications, devices, or procedures are informational and not endorsements. Full medical disclaimer.

†Some listed indications involve investigational/off-label use. Learn more.